Acurx Pharmaceuticals Gestione
Gestione criteri di controllo 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Dave Luci
Amministratore delegato
US$1.0m
Compenso totale
| Percentuale dello stipendio del CEO | 46.4% |
| Mandato del CEO | 6.8yrs |
| Proprietà del CEO | 6.8% |
| Durata media del management | Nessun dato |
| Durata media del Consiglio di amministrazione | 3.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely
Aug 11
Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Jan 22Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Oct 30Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?
Jul 15Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?
Mar 04Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Nov 16Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering
Jul 25Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
May 13Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Jan 22Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth
Sep 30New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers
Aug 27Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$16m |
| Jun 30 2024 | n/a | n/a | -US$17m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$475k | -US$15m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$12m |
| Dec 31 2022 | US$655k | US$475k | -US$12m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$4m | US$364k | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$596k | US$277k | -US$5m |
| Dec 31 2019 | US$290k | US$267k | -US$6m |
Compensazione vs Mercato: La retribuzione totale di Dave ($USD 1.02M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 647.72K ).
Compensazione vs guadagni: La retribuzione di Dave è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Dave Luci (57 yo)
6.8yrs
Mandato
US$1,023,878
Compensazione
Mr. David P. Luci, also known as Dave, CPA, J.D. Esq. served as Chairman of the Board at AMERI Holdings, Inc. since August 16, 2018 until December 12, 2018.Mr. Luci is the Co-Founder of Acurx Pharmaceutic...
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 6.8yrs | US$1.06m | 5.94% $ 1.1m | |
| Co-Founder | 6.8yrs | US$1.02m | 6.76% $ 1.3m | |
| Independent Director | 3.3yrs | US$78.94k | 0.019% $ 3.6k | |
| Independent Director | 3.3yrs | US$73.94k | 0.0095% $ 1.8k | |
| Independent Director | 3.3yrs | US$76.44k | 0.077% $ 14.8k | |
| Independent Director | 6.1yrs | US$66.44k | 0.72% $ 139.4k | |
| Independent Director & Scientific Advisor | 3.3yrs | US$61.44k | 0.11% $ 21.0k | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Scientific Advisor | no data | Nessun dato | Nessun dato |
3.3yrs
Durata media
71yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ACXP sono considerati esperti (durata media dell'incarico 3.3 anni).